Document is current

Article History

Received: 4 January 2023

Accepted: 29 January 2025

First Online: 15 February 2025

Declarations

:

: The study was approved by the Ethics Review Committee of Royal Canin SAS (protocol code RCIBD-2012, Nov 5, 2012). All dogs had active disease and the clinical procedures used were required for the management of their case. All procedures were conducted in accordance with relevant guidelines (e.g., standard operating procedures) and regulations. The food used in the study was a commercially-available therapeutic diet that was already commonly used by veterinarians for CE, and was fed for the clinical benefit of the study dogs. In the ethical approval granted (protocol code RCIBD-2012), neither the clinical procedures used nor the clinical use of the therapeutic diets were deemed to involve animal experimentation and, therefore, fell outside the remit of national legislation. The owners of all participating dogs gave their informed consent in writing, for clinical management of their CE, for the use of anonymised data and surplus clinical samples for research purposes, and for use of data for publication. All procedures performed were clinical in nature and undertaken for the benefit of the animal.

: Not applicable.

: VB and JL are current employees of Royal Canin SAS, whilst IM was also an employee at the time of the research. Although AJG is an employee of the University of Liverpool, his post is financially supported by Royal Canin. AJG has also received financial remuneration for providing educational material, speaking at conferences, and consultancy work from this company; all such remuneration has been for projects unrelated to the work reported in this manuscript. Royal Canin collaborated on the design of the study, supplied the test diet, performed some of the statistical analyses, participated in the decision to publish the results, funded editorial support and reviewed the manuscript for quality purposes prior to submission.